Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Overview
Explore Madrigal Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
12.4B
P/E Ratio
-50.21
EPS (TTM)
$-13.47
ROE
-0.50%
MDGL Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Madrigal Pharmaceuticals, Inc. (MDGL) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 58.69, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $519.32.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -50.21 and a market capitalization of 12.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.